European regulators link tirzepatide to dysesthesia and delayed gastric emptying

European regulators have concluded that tirzepatide, sold in the United States as Mounjaro and Zepbound, can cause dysesthesia and delayed gastric emptying, and that product information for the drug in the European Union must be changed to say so ^[1].

The conclusion is dated 12 December 2024 and comes from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency ^[1]. It follows a review of a periodic safety update report for tirzepatide covering 14 September 2023 through 13 May 2024, under procedure number EMEA/H/C/PSUSA/00011019/202405 ^[1].

What regulators concluded

The Pharmacovigilance Risk Assessment Committee (PRAC) reviewed data on dysesthesia — a term for abnormal, unpleasant sensations — from clinical trials and from spontaneous reports, "including in some cases a close temporal relationship, a positive de-challenge and/or re-challenge," along with a plausible mechanism of action ^[1]. A positive de-challenge means symptoms eased when the drug was stopped; a positive re-challenge means they came back when it was restarted.

On that basis, the PRAC decided that "a causal relationship between tirzepatide and dysaesthesia is at least a reasonable possibility" ^[1].

The committee reached the same conclusion for delayed gastric emptying, citing the same types of evidence: clinical trial data, spontaneous reports with close timing, de-challenge or re-challenge findings, and a plausible mechanism ^[1].

The PRAC concluded that the product information for products containing tirzepatide should be amended accordingly, and the CHMP agreed with its overall conclusions and grounds ^[1].

Benefit-risk balance unchanged

The CHMP said the benefit-risk balance of tirzepatide products "is unchanged subject to the proposed changes to the product information," and recommended that the terms of the marketing authorisations be varied ^[1]. In other words, the action is a labeling change, not a finding that the drug should be pulled from the market.

Why it matters for patients

The conclusion means European labels for tirzepatide will describe dysesthesia and delayed gastric emptying as possible side effects of the drug itself. According to this document, that wording is being added through the variation the CHMP recommends ^[1].

For people in the United States, the practical effect is unclear. This document covers EU marketing authorisations only. Whether the US Food and Drug Administration will require similar wording in US prescribing information for Mounjaro or Zepbound has not been reported, and no US action on these two events has been disclosed.

Both events describe things patients can notice. Dysesthesia refers to abnormal sensations. Delayed gastric emptying means the stomach empties more slowly than usual. The document does not give incidence rates, does not say how often the events were serious, and does not say how long they lasted.

The review covered reports filed between September 2023 and May 2024, so it reflects what EU regulators had on file by the end of that window, not later data ^[1].

What happens next

The CHMP has recommended varying the terms of the marketing authorisation for tirzepatide products ^[1]. The document sets out the scientific conclusions and the grounds for that change, but a date for when revised EU product information takes effect has not been reported. No timeline for any US review of the same two events has been disclosed.